Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 in hemophilia A switching from emicizumab
NCT05878938Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Treatment-Emergent Adverse Events at 26 weeks. Started Jun 2023; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05878938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878938.